Inhibrx Biosciences Inc.
INBX | NASDAQ
$112.04
+$2.69 (+2.46%)
At close: Sep 21, 2026, 4:00 PM ET
$112.04
$0 (0.00%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 1.3M | 200K | 1.8M | 2.19M | 7.23M | 12.81M |
Cost of Revenue | 2.48M | 2.29M | 1.19M | 110.19M | n/a | 73.5M |
Gross Profit | -1.18M | -2.09M | 609K | -107.99M | 7.23M | -60.69M |
Operating Income | -135.03M | -331.45M | -219.22M | -129.12M | -76.56M | -67.44M |
Interest Income | 7.55M | 10.94M | 11.92M | 16.11M | n/a | 10.82M |
Pretax Income | -140.05M | 1.69B | -239.72M | -145.22M | -81.77M | -75.63M |
Net Income | -140.06M | 1.69B | -241.36M | -145.23M | -81.77M | -75.64M |
Selling & General & Admin | 23.3M | 127.91M | 29.38M | 21.12M | 12.36M | 6.84M |
Research & Development | 113.03M | 203.74M | 190.65M | 110.19M | 71.44M | 73.5M |
Other Expenses | -2.48M | -2.29M | -199K | -110.19M | n/a | -80K |
Operating Expenses | 133.84M | 329.36M | 219.83M | 21.12M | 83.8M | 80.25M |
Interest Expense | 12.2M | 13.49M | 31.84M | 16.11M | 5.22M | 10.82M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 136.33M | 331.65M | 221.02M | 131.3M | 83.8M | 80.25M |
Income Tax Expense | 2K | 2K | 3K | 3K | 2K | 3K |
Shares Outstanding (Basic) | 15.49M | 14.48M | 47.13M | 40.11M | 38.01M | 25.26M |
Shares Outstanding (Diluted) | 15.49M | 14.48M | 47.13M | 40.11M | 38.01M | 25.26M |
EPS (Basic) | -9.04 | 116.58 | -5.12 | -3.62 | -2.15 | -2.99 |
EPS (Diluted) | -9.04 | 116.58 | -5.12 | -3.62 | -2.15 | -2.99 |
EBITDA | -125.37M | 1.7B | -206.69M | -125.82M | -76.55M | -63.8M |
EBIT | -127.86M | 1.7B | -207.88M | -127.04M | -76.55M | -64.82M |
Depreciation & Amortization | 2.48M | 2.29M | 1.19M | 1.23M | n/a | 1.02M |
Add to Watchlist
Select watchlists to add or remove INBX